N/A N=312 Randomized Prevention

CATCH-UP Vaccines: Engaged Approaches to Testing in Community/Healthcare Settings for the Underserved (COVID-19)

COVID-19 · Vaccine Refusal

Bottom Line

View on ClinicalTrials.gov: NCT05236270 ↗

Enrolled (actual)

312

Serious AEs

0.0%

Results posted

Apr 2024

Primary outcome: Primary: Percentage of Participants Who Plan to Receive a COVID-19 Vaccine Post-intervention — 19; 24; 19; 21 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Text Message (Behavioral); Motivational Interviewing (Behavioral); Electronic Educational Message with Tailored Questions/Prompts (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Oklahoma
Primary completion: Jun 2023

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage of Participants Who Plan to Receive a COVID-19 Vaccine Post-intervention	19; 24; 19; 21; 24; 19	—
SECONDARY Percentage of Participants Who Self-report COVID-19 Vaccine Uptake	2; 1; 0; 0; 2; 1	—

Summary

Oklahoma has high COVID-19 incidence, particularly among underserved minority and rural Oklahomans. Oklahoman's are also reporting SARS-CoV-2 vaccine hesitancy and signs of slowing vaccine uptake, with increased hesitancy among American Indian and rural populations. The project aims to work with ongoing community testing events to implement interventions to improve vaccine uptake among Oklahoma's underserved populations.

Eligibility Criteria

Inclusion Criteria

18 years of age and older
Must be eligible to receive a COVID-19 vaccine dose at the time of consent based on the following criteria:

a. Eligible for one bivalent mRNA vaccine i. No previous doses of any COVID-19 vaccine ii. At least 8 weeks since a previous vaccine dose of any manufacturer b. Eligible for second bivalent mRNA vaccine i. Adults 65 year of age and older can receive one additional bivalent mRNA vaccine at least 4 months after the first dose of a bivalent mRNA vaccine.

ii. Those who are immunocompromised can receive one additional bivalent mRNA vaccine at least 2 months after the first dose of a bivalent mRNA vaccine.

Ability to read and speak English

Exclusion Criteria

Those who have received all eligible doses of any approved COVID-19 vaccine.
Those with active COVID-19 disease (either through self-reported positive test within the last 10 days or viral test at the event if available).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05236270). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.